Type 2 Diabetes Clinical Trial
— Fit4LifeOfficial title:
Effect of a Community-based Sport Programme on Disease Symptoms and Quality of Life in Men and Women With Type 2 Diabetes
The Fit4Life intervention aims to engage inactive patients with type 2 diabetes in a
community-based sport intervention, with the aim being that all participants complete 1 x 30
min session of physical activity/exercise per week across the 12 months they are involved in
the intervention (total study duration 3 years).
The aim of the Fit4Life intervention is to slow the progression of disease symptoms and to
improve quality of life in those diagnosed with type 2 diabetes. The aim of this research
study is thus to evaluate the effectiveness of the intervention in achieving these aims. The
hypothesis is that involvement in the Fit4Life programme will increase physical activity,
reduce type 2 diabetes disease symptoms and enhance self-reported quality of life in male
and female patients aged 35-64.
Status | Not yet recruiting |
Enrollment | 4032 |
Est. completion date | June 2019 |
Est. primary completion date | December 2018 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 35 Years to 64 Years |
Eligibility |
Inclusion Criteria: - type 2 diabetic - inactive Exclusion Criteria: - taking part in regular sport or physical activity (more than 30 minutes on one day per week) |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | Nottingham Trent University | Nottingham |
Lead Sponsor | Collaborator |
---|---|
Nottingham Trent University | Community Sport Trust, NHS North and East Nottinghamshire Clinical Commissioning Group, NHS Nottingham City Clinical Commissioning Group, NHS Rushcliffe Clinical Commissioning Group, NHS West Nottinghamshire Clinical Commissioning Group, Nottingham City Council, Nottinghamshire County Council, Sport England, Sport Nottinghamshire |
United Kingdom,
Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003 Aug;35(8):1381-95. — View Citation
Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the International Physical Activity Questionnaire Short Form (IPAQ-SF): a systematic review. Int J Behav Nutr Phys Act. 2011 Oct 21;8:115. doi: 10.1186/1479-5868-8-115. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in number of participants reporting one or more sessions of sport per week measured by the UK Single Item Questionnaire | 3 years | No | |
Secondary | Change from baseline in body mass (kg) | 3 years | No | |
Secondary | Change from baseline in hip circumference (cm) | 3 years | No | |
Secondary | Change from baseline in waist circumference | 3 years | No | |
Secondary | Change from baseline in quality of life as measured by the quality of life survey (QOLS)(sum of 16 item 7 point likert scale) | 3 years | No | |
Secondary | Change from baseline in control of blood glucose concentration as measured by self-report survey (subjective rating, 'better', 'the same', 'worse' | 3 years | No | |
Secondary | Change from baseline in control of blood glucose concentration as measured by HPA1c (mmol/mol) | 3 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |